Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012 - Wikidata - wikimedia - TriplyDB

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

http://www.wikidata.org/entity/Q57660820

about

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children From the microbiome to the central nervous system, an update on the epidemiology and pathogenesis of bacterial meningitis in childhood Population structure of invasive Streptococcus pneumoniae isolates among Alaskan children in the conjugate vaccine era, 2001 to 2013.Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.Profiling pneumococcal type 3-derived oligosaccharides by high resolution liquid chromatography-tandem mass spectrometry.Reply to Farkouh RA et al. Comment on "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children"Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012-2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes.Molecular characterization of penicillin non-susceptible Streptococcus pneumoniae isolated before and after pneumococcal conjugate vaccine implementation in Casablanca, Morocco.Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age.Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.Glycoconjugate vaccines: an update.Streptococcus pneumoniae serotype 19A: Worldwide epidemiology.Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.Assessing the diagnostic accuracy of PCR-based detection of Streptococcus pneumoniae from nasopharyngeal swabs collected for viral studies in Canadian adults hospitalised with community-acquired pneumonia: a Serious Outcomes Surveillance (SOS) Netwo Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians Lignes directrices pour la prise en charge de la méningite bactérienne présumée ou confirmée chez les enfants canadiens de plus d’un mois.T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in N Evaluation of the Enhanced Invasive Pneumococcal Disease Surveillance System (eIPDSS) Pilot Project.

P2860

Q26782280-0B70C624-87D5-400F-8AE4-664C88E6B656 Q29248091-1C75FC39-3D55-4189-B63E-EC28BC58E6ED Q30151859-B8C40E82-6C73-4D0E-90D9-0FF0E3D80873 Q33653107-01EBCE43-B4D0-44A3-BCC7-157444535E54 Q35588956-7E0E92C5-2C98-452A-AB67-F92863D88ABD Q35752770-34DE4B8A-8F4F-42C7-9E68-583E7B4EF105 Q35796784-41F293A3-4F06-4EF7-8BA5-CD7D37A2904E Q35867061-4EB9D0E7-044F-4E1C-8688-448D073E0FE8 Q35887787-EEDBC22F-BAA2-40A0-89E5-182228316B3B Q36176772-5E5DBCA3-E2AB-44BF-8517-5600756DC6FD Q36334808-9CA3B66A-135F-4CBB-8D0F-1FD813BEEFC7 Q37197138-8454074F-E480-4E50-B4D5-BFD997AE6F4F Q37375921-8C76FE81-E98F-4DAA-8A8E-F3F6FBE4E42B Q37633201-7868D908-6EA0-406A-993D-6002537EE3AB Q37649380-978277CE-8CDA-48B6-A4F8-14318833FBBD Q38255287-DA5747A1-A4E9-4D80-9C0D-B4E562CA2E6E Q38286346-19289C76-CF4D-48DE-A830-56F5F91388CD Q38637072-4BD96800-13A1-426C-817F-6C35F6374C81 Q38956348-AD0736C4-2333-4720-958A-A8C49A20734D Q39093634-F2623C3E-83EF-426A-B424-9A08BC3C6A36 Q40165370-DEA77079-6F42-4760-8F90-B295330DBE53 Q41383702-AAB9B05E-B9AB-4C10-9B81-5AD28FE0C4EC Q41471703-9E4FAE61-FA8A-49C1-9176-86308F1EA719 Q42200242-534E11CF-E301-4A21-8F2B-08985590E8AD Q42419675-3D72BCE3-1234-484A-BE65-225B72BCF5C7 Q46122731-8BC33250-8E72-4189-A954-B4BC9A934F7A Q48348733-1E4C2F43-E0B1-4CFE-805F-6C78EB19FA62 Q52597282-69DE0974-7467-4A97-85F1-06DFC02F55A7 Q54208077-392CCF2D-3646-4F50-92F0-308086F0C765

P2860

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

http://www.wikidata.org/entity/Q57660820

description

article

@en

im Dezember 2013 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2013

@uk

name

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@en

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@nl

type

label

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@en

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@nl

prefLabel

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@en

Serotype distribution of invas ...... l conjugate vaccine, 2010–2012

@nl

P1433

Q57660820-FE0D26B2-F242-4521-83C9-38B5F8A10CEC

P1476

Q57660820-46E25091-C63C-46E4-95E7-B5E976746337

P2093

Q57660820-0B9F0301-EB6E-4B79-871F-6555A071E0B6

Q57660820-178DC0C5-706E-4831-9A28-122767A3492A

Q57660820-1E9888F7-1870-47BA-B9F7-6D05EDDD1761

Q57660820-2FDA8C49-4BC8-4445-8A41-746147BAF734

Q57660820-36DC58E6-7FCC-46CD-BE38-47C395AD434D

Q57660820-AC23274E-C0C9-45F2-BE8A-15039E24C2E7

Q57660820-AC6A4C5A-4E1D-4D40-A9C6-01C4B6456789

Q57660820-C96DACBB-0F8F-4DD0-A3B1-980CF0507C5B

Q57660820-D6AC85D2-7D1C-4F12-9114-BB0EF2D79E30

Q57660820-E02CD171-6076-42AE-B00A-EE73F7D2776B

P2860

Q57660820-02B30406-9572-46EF-86CE-F99D19D853F8

Q57660820-232FBFC1-21A4-4091-8134-2BB04AA26AC8

Q57660820-3672ABBF-4E42-4A4D-96AD-19F09BD13E22

Q57660820-4477C110-D5C3-4BD6-980E-D9413E366D7D

Q57660820-46222263-A735-4980-A705-9EDE5D970C9F

Q57660820-4C37F0E5-3984-4EBC-9B62-361F0FA8E301

Q57660820-4CE3925C-033F-4ED3-AA81-43BFA5BAFAB0

Q57660820-50ABA34C-A23A-4892-A8D2-C95215916BC7

Q57660820-5BD9D07D-D573-42C0-9F1E-DD5D4250EB8F

Q57660820-5C1FEA66-E738-4EA6-965A-8862AC180EF6

P304

Q57660820-01988A8D-56F1-49C6-99E0-6207380364BB

P31

Q57660820-704996D0-926C-4CEF-B894-6076DDC93ACD

P356

Q57660820-C5D5A841-EEE4-4BBA-A3E6-B930AB948A67

P433

Q57660820-DB5E4D18-F5CF-4B17-BBF7-91A7A1ECDB27

P478

Q57660820-C741B929-E640-449C-82EE-C482AC9D7397

P50

Q57660820-304249BB-4BB6-4A65-AADF-B2EF84BF531D

Q57660820-56AAF10E-DFB0-4958-9113-7B5FC8A6478F

Q57660820-CC1A9366-534D-4EC0-8EA9-EAF449D8536F

P577

Q57660820-FACFEC92-5316-4DB6-B6D2-73D5C281D8C9

P698

Q57660820-AC16D0EE-CE01-4E1D-AB48-42E0B3EF40E4

P356

P1433

Canadian Journal of Microbiology

P1476

Serotype distribution of invas ...... l conjugate vaccine, 2010-2012

@en

P2093

Averil Griffith

http://www.w3.org/2001/XMLSchema#string

Brigitte Lefebvre

http://www.w3.org/2001/XMLSchema#string

Canadian Public Health Laboratory Network

http://www.w3.org/2001/XMLSchema#string

Gregory J Tyrrell

http://www.w3.org/2001/XMLSchema#string

Heather Adam

http://www.w3.org/2001/XMLSchema#string

Irene Martin

http://www.w3.org/2001/XMLSchema#string

Lindsey Sherrard

http://www.w3.org/2001/XMLSchema#string

Marguerite Lovgren

http://www.w3.org/2001/XMLSchema#string

Matthew Gilmour

http://www.w3.org/2001/XMLSchema#string

Shalini Desai

http://www.w3.org/2001/XMLSchema#string

P2860

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005

Two cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure.

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009.

Serotype replacement in disease after pneumococcal vaccination

Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination.

Efficacy of pneumococcal vaccination in adults: a meta-analysis.

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

Pneumococcal serotypes in children in 4 European countries

P304

778-788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1139/CJM-2013-0614

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

George G Zhanel

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24313450

http://www.w3.org/2001/XMLSchema#string